Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics has presented positive preclinical data on its proprietary product candidate peg-irinotecan. The data highlighted the anti-tumor activity and unique pharmacokinetic profile of peg-irinotecan in preclinical models of colorectal, lung and breast cancer.
Subscribe to our email newsletter
NKTR-102 (Peg-irinotecan) is a pegylated form of irinotecan developed using Nektar’s innovative small molecule pegylation technology platform. NKTR-102 inhibited tumor growth by greater than 90% in mouse xenograft models of colorectal (HT29), lung (NCI- H460) and breast (MCF-7) cancers as compared to controls.
The studies also demonstrate that Nektar’s small molecule pegylation technology improves the pharmacokinetics of irinotecan by increasing the effective half-life of irinotecan’s active metabolite in tumor tissues. In a colorectal cancer model, the half-life was increased to 15 days following NKTR-102 administration versus four hours following irinotecan.
Hoyoung Huh, COO and head of the pegylation business unit at Nektar, said: “NKTR-102 demonstrates improved half-life and tumor exposure to irinotecan’s active metabolite, effectively inhibiting the cellular replication process in solid tumors. These findings validate the potential of our small molecule pegylation technology platform to improve a wide range of oncolytics in critical cancer treatment regimens.”